These results suggest that ERα+/PR+/HER2− tumor cells (MCF7 and ZR751), with intermediate CIN, respond better to treatment with taxanes (DOC) and to combined treatments with TAM+DOX compared with the treatment with anthracyclines and with TAM+DOC. The gene discussed is ERBB2; the disease is neoplasm.